Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Recently published studies highlight enhanced cardiovascular health benefits from adding Natreon's Crominex®3+ to fish oil supplementation

Natreon announces the publication of two clinical trials evaluating the effectiveness of fish oil alone and with Crominex®3+ trivalent chromium complex on vascular endothelial function, triglyceride and cholesterol levels, and other parameters of cardiovascular health.


News provided by

Natreon

Jul 15, 2021, 10:00 ET

Share this article

Share toX

Share this article

Share toX


NEW BRUNSWICK, N.J., July 15, 2021 /PRNewswire-PRWeb/ -- Natreon announces the publication of two clinical trials evaluating the effectiveness of fish oil alone and with Crominex®3+ trivalent chromium complex on vascular endothelial function, triglyceride and cholesterol levels, and other parameters of cardiovascular health. Chromium supports the actions of insulin in the body to influence these parameters and others associated with cardiovascular and metabolic health. The clinical trials build on prior clinical studies demonstrating superior cardiovascular health benefits, including improved vascular function, of Crominex®3+ compared to other forms of chromium used in dietary supplements such as Cr-picolinate and Cr-polynicotinate.

Fish oil-derived omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are among the most popular supplements used to support cardiovascular health as many do not consume enough naturally from certain fatty fish in the diet. However, mixed results from clinical studies have contributed to controversy on the effectiveness of fish oil supplementation for cardiovascular health. Higher doses of omega-3 supplementation appear to be more beneficial and multiple prescription-strength omega-3 fatty acid products providing gram quantities of EPA or EPA + DHA have been approved by the FDA for reducing elevated levels of triglycerides, whereas many omega-3 dietary supplements do not provide such quantities per serving. Furthermore, obtaining gram amounts of omega-3 fatty acids from fish and fish oil supplements can be rather expensive, so cost prohibitive for many people.

"These clinical trials show a consistent pattern of significantly enhanced cardiovascular and metabolic health benefits with the addition of Crominex®3+ to fish oil supplementation, potentially reducing the amount of fish oil needed to be effective in those that stand to benefit most."

Post this

Two randomized, double-blind, placebo-controlled clinical trials in two different populations, one in people with metabolic syndrome and another in type 2 diabetics receiving stable metformin therapy, both characterized by insulin resistance, elevated blood sugar and lipids, and vascular endothelial dysfunction, so diminished cardiovascular health, were conducted to evaluate daily supplementation with 2 g fish oil, providing 1 g of EPA + DHA, with or without Crominex®3+ at two different doses (10 mg providing 200 mcg Cr or 20 mg providing 400 mcg Cr) on cardiovascular health parameters. Although significant improvements in most parameters were observed with fish oil supplementation for 12 weeks in both trials, improvements were significantly, and dose-dependently, greater with the addition of Crominex®3+ to fish oil supplementation. Vascular endothelial function improved ~32% and ~77% on average with the fish oil supplementation in people with metabolic syndrome and type 2 diabetes, respectively, but improved ~240% and ~381% on average in those same populations when also supplemented with 20 mg of Crominex®3+.

Dr. Sanni Raju, CEO of Natreon, stated, "these clinical trials show a consistent pattern of significantly enhanced cardiovascular and metabolic health benefits with the addition of Crominex®3+ to fish oil supplementation, potentially reducing the amount of fish oil needed to be effective in those that stand to benefit most. The cost of adding 20 mg Crominex®3+ to fish oil is very cheap, so this would be far more cost effective. Who wouldn't want to improve the effectiveness of fish oil supplementation if cheap and safe? The cost to benefit ratio is clear."

About Crominex®3+:
Crominex®3+ trivalent chromium complex overcomes limitations of other commercially available chromium ingredients by combining chromium (chloride) with the potent antioxidant powerhouse superfruit ingredient, Capros® amla extract, to stabilize and prevent oxidation of trivalent chromium, as well as fulvic acid rich PrimaVie® purified shilajit extract, to support chromium solubility and absorption. Two randomized, double-blind, placebo-controlled clinical trials have shown that dietary supplementation with Crominex®3+ trivalent chromium complex is significantly more effective than other commercially available chromium ingredients (at equivalent dosing of elemental chromium), including Cr-picolinate, Cr-polynicotinate, Cr-dinicocysteinate, and Cr-chloride, for discouraging oxidative stress and supporting healthy levels of sugar, fat, and cholesterol in circulation as well as functioning of blood vessels, all indicators of improved insulin activity in the body.    

About Natreon
Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon's patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon's ingredients have been used in over 50 clinical trials that have supported 40 publications and 24 active patents. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India. Natreon's products include: Sensoril® ashwagandha, PrimaVie® shilajit, Capros® amla, Crominex®, AyuFlex®, Ayuric®, and introducing PhytoBGS®. For more information, visit: https://natreoninc.com/.

Contact:
Ally Coda – Marketing & Public Relations
Natreon, Inc.
2-D Janine Place
New Brunswick, NJ 08901
Tel: 732-296-1080
E-mail: [email protected]

Media Contact

Ally Coda, Natreon, 732-296-1080, [email protected]

Twitter, LinkedIn, Facebook

SOURCE Natreon

Related Links

https://natreoninc.com/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.